Furthermore, a clinical study also showed that the ratio of glucagon/insulin in blood levels could be used as a potential biomarker to differentiate type 2 diabetes mellitus from pancreatic cancer-related diabetes mellitus, suggesting that the measurement of the glucagon/insulin ratio might improve early diagnosis in a subset of patients with new onset diabetes [15]. This evidence concerns the gene GCG and pancreatic neoplasm.